focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Ark Therapeutics Group plc

15 Feb 2013 10:39

ABERFORTH PARTNERS LLP - Form 8.3 - Ark Therapeutics Group plc

ABERFORTH PARTNERS LLP - Form 8.3 - Ark Therapeutics Group plc

PR Newswire

London, February 15

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A

PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Identity of the person whose positions/ Aberforth Partners LLP, ondealings are being disclosed:

behalf of discretionary clients.(b) Owner or controller of interests and shortpositions disclosed, if different from 1(a):The naming of nominee or vehicle companies isinsufficient

(c) Name of offeror/offeree in relation to Ark Therapeutics Group plcwhose relevant securities this form relates:

Use a separate form for each offeror/offeree(d) If an exempt fund manager connected withan offeror/offeree, state this and specifyidentity of offeror/offeree:(e) Date position held/dealing undertaken: 14 February 2013(f) Has the discloser previously disclosed, or Y/N NOare they today disclosing, under the Code in

respect of any other party to this offer? If YES, specify which:

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a) Interests and short positions in the relevant securities of the offeror orofferee to which the disclosure relates following the dealing (if any)

Class of relevant security: Ordinary Shares Interests Short positions Number % Number %(1) Relevant securities owned 24,580,092 11.75 0 0.0and/or controlled:(2) Derivatives (other thanoptions):(3) Options and agreements topurchase/sell:TOTAL: 24,580,092 11.75 0 0.0

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchaseor sell relevant securities, should be given on a Supplemental Form 8 (OpenPositions).

(b) Rights to subscribe for new securities (including directors' and otherexecutive options)

Class of relevant security in N/Arelation to which subscription rightexists:Details, including nature of the N/Arights concerned and relevantpercentages:

If there are positions or rights to subscribe to disclose in more than oneclass of relevant securities of the offeror or offeree named in 1(c), copytable 2(a) or (b) (as appropriate) for each additional class of relevantsecurity.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a) Purchases and sales

Class of relevant Purchase/sale Number of Price per unit security securities Ordinary Shares Sale 1,930,000 1.025p

(b) Derivatives transactions (other than options)

Class of Product Nature of dealing Number of Price per relevant description reference unit security e.g. opening/closing a securities e.g. CFD long/short position, increasing/reducing a long/short position N/A

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Optionrelevant description purchasing, securities price

date moneysecurity e.g. call selling, to which per unit e.g. paid/ option varying option American, received etc. relates European per unit etc. N/A(ii) Exercising Class of relevant Product Number of Exercise price per security description securities unit e.g. call option N/A

(d) Other dealings (including subscribing for new securities)

Class of relevant Nature of dealing Details Price per unit

security (if applicable) e.g. subscription, conversion N/A

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities ofthe offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (asappropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement orunderstanding, formal or informal, relating to relevant securities which maybe an inducement to deal or refrain from dealing entered into by the personmaking the disclosure and any party to the offer or any person acting inconcert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

None

(b) Agreements, arrangements or understandings relating to options orderivatives

Details of any agreement, arrangement or understanding, formal or informal,between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevantsecurities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None(c) AttachmentsIs a Supplemental Form 8 (Open Positions) attached? Y/N NODate of disclosure: 15 February 2013Contact name: David Holland, for Aberforth Partners LLPTelephone number: 0131 220 0733

Public disclosures under Rule 8 of the Code must be made to a RegulatoryInformation Service and must also be emailed to the Takeover Panel atmonitoring@disclosure.org.uk . The Panel's Market Surveillance Unit isavailable for consultation in relation to the Code's dealing disclosurerequirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Date   Source Headline
2nd Jun 20154:55 pmRNSChange of Auditor
29th May 20157:00 amRNSHalf Yearly Report
7th May 20153:42 pmRNSChange of Registered Office
29th Apr 20157:01 amRNSTrading Statement
29th Apr 20157:00 amRNSFinal Results
13th Mar 201511:22 amRNSHolding(s) in Company
9th Mar 20157:00 amRNSRenamed Premier Veterinary Group
3rd Mar 201512:33 pmRNSHolding(s) in Company
3rd Mar 20159:48 amRNSHolding(s) in Company
2nd Mar 20152:36 pmRNSHolding(s) in Company
2nd Mar 201510:55 amRNSHolding(s) in Company
2nd Mar 201510:42 amRNSHolding(s) in Company
27th Feb 20154:35 pmRNSPrice Monitoring Extension
27th Feb 20154:07 pmRNSBoard Changes and Directors' Dealings
27th Feb 20158:00 amRNSCancellation
27th Feb 20157:00 amRNSAdmission to the Official List
26th Feb 20154:00 pmRNSCancellation and Publication of Prospectus
5th Feb 20154:22 pmRNSAcquisition completed
28th Jan 20159:29 amRNSSale and Purchase Agreement Signed
15th Jan 20157:00 amRNSTransfer of listing category on the Official List
4th Dec 201411:17 amRNSBlocklisting Interim Review
21st Nov 20145:48 pmRNSPosting of Circular
1st Aug 20147:00 amRNSHalf Yearly Report and Change of Registered Office
1st Jul 20147:00 amRNSResults of AGM and Board Changes
3rd Jun 20147:00 amRNSBlocklisting Interim Review
13th May 20147:00 amRNSInterim Management Statement
30th Apr 20147:00 amRNSFinal Results
28th Mar 20147:45 amRNSSuspension - Ark Therapeutics Group Plc
28th Mar 20147:32 amRNSSigned Heads of Terms and Suspension of Trading
25th Mar 201412:48 pmRNSHolding(s) in Company
4th Mar 201412:22 pmRNSHolding(s) in Company
21st Feb 20144:40 pmRNSSecond Price Monitoring Extn
21st Feb 20144:35 pmRNSPrice Monitoring Extension
20th Feb 201410:44 amRNSHolding(s) in Company
20th Feb 201410:39 amRNSHolding(s) in Company
20th Feb 201410:38 amRNSHolding(s) in Company
6th Dec 20135:46 pmRNSBlocklisting Interim Review
6th Nov 20137:00 amRNSInterim Management Statement
8th Oct 201311:27 amRNSHolding(s) in Company
7th Oct 20134:35 pmRNSPrice Monitoring Extension
7th Oct 20133:21 pmRNSHolding(s) in Company
27th Sep 201311:46 amRNSHolding(s) in Company
26th Sep 20133:26 pmRNSHolding(s) in Company
24th Sep 201311:02 amRNSHolding(s) in Company
20th Sep 201311:47 amRNSHolding(s) in Company
18th Sep 20134:40 pmRNSSecond Price Monitoring Extn
18th Sep 20134:35 pmRNSPrice Monitoring Extension
17th Sep 201310:00 amRNSHolding(s) in Company
13th Sep 201311:40 amRNSHolding(s) in Company
10th Sep 201310:37 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.